Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation sequencing becomes embedded in routine care than the small differences between them.

Four of the therapies are poised to enter the market within the next year, targeting narrow slices of the non-small cell lung cancer (NSCLC) patient population not yet served by tumor-targeted agents. ...